Investigate / DVA
Understand DAVITA INC.
Can DaVita sustain dialysis profitability if commercial payor terms or patient mix become less favorable?
Snapshot reviewed 2026-10-02. Source published 2026-08-04. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / DVA
Ask better questions. Keep the evidence.
Explore the available sources for DAVITA INC., then keep what deserves another look.
01 Investor activity
Who reports owning DVA?
2 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
Inspect all owners, reported changes and filing dates →02 Business evidence
Reported evidence
What does the company do?
DaVita’s largest business provides U.S. dialysis and related laboratory services for patients with chronic kidney failure, within its wider kidney-care platform.
Latticework interpretation
What could support the case?
If DaVita successfully implements integrated kidney-care, value-based-care and home-dialysis initiatives, those strategies could support its business.
Latticework interpretation
What could break the case?
If commercial payment rates fall or fewer patients use commercial plans, DaVita could face pressure on profits concentrated in those higher-paying plans.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
DaVita’s largest business provides U.S. dialysis and related laboratory services for patients with chronic kidney failure, within its wider kidney-care platform.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $3,554.084m | $3,379.526m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $579.001m | $537.841m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $265.397m | $199.337m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $810.9m | $504.245m |
Comparison caveat: Operating cash covers the half-year and benefits from collections and working-capital improvements. Prior-period collections were disrupted by a cybersecurity incident, so cash growth is not solely recurring profit growth.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If DaVita successfully implements integrated kidney-care, value-based-care and home-dialysis initiatives, those strategies could support its business.
Supporting filing ↗The strongest caution
If commercial payment rates fall or fewer patients use commercial plans, DaVita could face pressure on profits concentrated in those higher-paying plans.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How dependent are results on commercial payors?
Starting evidence: Profits are described as concentrated in commercial plans facing downward rate pressure, making payor negotiations and patient mix potentially important to results.
Investigate next: Review payor mix disclosures, contract renewal timing, and commentary on commercial rate trends in the full filings.
Read the supporting filing ↗What drives labor and supplier cost exposure?
Starting evidence: The business is labor intensive, so labor cost increases or difficulty retaining employees could affect operations.
Investigate next: Examine labor cost discussion, contract labor use, and any supplier concentration or pricing disclosures.
Read the supporting filing ↗Can value-based care initiatives scale as intended?
Starting evidence: Success of integrated kidney care and value-based strategies may be affected by changes to government contracting models.
Investigate next: Investigate enrollment in risk-based arrangements, program economics, and the effect of any model changes on results.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.